Compare

Lexeo Therapeutics, Inc. vs Tectonic Therapeutic, Inc. vs Invivyd, Inc. vs Coherus Oncology, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Lexeo Therapeutics, Inc. LXEO	Tectonic Therapeutic, Inc. TECX	Invivyd, Inc. IVVD	Coherus Oncology, Inc. CHRSRevenue covers only part of its income (partial revenue)
Year ended	2025-12-31	2025-12-31	2025-12-31	2025-12-31
Revenue	n/a	n/a	$53.43M	n/a
Revenue growth (YoY)	n/a	n/a	+110.5%	n/a
Gross margin	n/a	n/a	n/a	n/a
Operating margin	n/a	n/a	-104.0%	n/a
Net margin	n/a	n/a	-98.2%	n/a
Net income	-$99.96M	-$74.15M	-$52.49M	$168.02M
EPS (Diluted)	-$1.86	-$4.05	-$0.30	$1.43
Operating cash flow	-$98.56M	-$60.08M	-$58.13M	-$138.51M
Free cash flow	-$98.96M	-$60.29M	-$58.29M	n/a
Cash & equivalents	$63.00M	$253.80M	$226.69M	$88.88M
Total assets	$268.69M	$261.04M	$276.88M	$258.34M
Total liabilities	$22.02M	$9.71M	$35.34M	$197.33M
Shareholders' equity	$246.67M	$251.33M	$241.54M	$61.01M
Return on year-end equity	-40.5%	-29.5%	-21.7%	275.4%
Shares outstanding	73.00M	18.74M	281.99M	121.15M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Lexeo Therapeutics, Inc.	Tectonic Therapeutic, Inc.	Invivyd, Inc.	Coherus Oncology, Inc.
Latest	$654.0K Ended 2022-12-31	n/a	$53.43M Ended 2025-12-31	n/a
1 year earlier	n/a	n/a	$25.38M Ended 2024-12-31	n/a
2 years earlier	n/a	n/a	$0 Ended 2023-12-31	n/a
3 years earlier	n/a	n/a	n/a	n/a
4 years earlier	n/a	n/a	n/a	n/a